Maximum Dosage of SGLT2 Inhibitors in CKD
The maximum dosage of SGLT2 inhibitors for patients with type 2 diabetes and CKD is a fixed dose that does not require titration: dapagliflozin 10 mg once daily, empagliflozin 25 mg once daily (or 10 mg if 25 mg not tolerated), and canagliflozin 100 mg once daily for patients with eGFR 30-60 mL/min/1.73 m² (300 mg daily if eGFR ≥60). 1, 2, 3, 4
Dapagliflozin Dosing by eGFR
For cardiovascular and renal protection, dapagliflozin 10 mg once daily is the standard fixed dose regardless of eGFR level, as long as eGFR ≥20 mL/min/1.73 m². 5, 2, 3
eGFR ≥45 mL/min/1.73 m²: Initiate dapagliflozin 10 mg once daily for all indications (glycemic control, cardiovascular protection, renal protection). No dose adjustment needed. 1, 2
eGFR 25-44 mL/min/1.73 m²: Initiate dapagliflozin 10 mg once daily for cardiovascular/renal protection. Do NOT initiate for glycemic control alone, as glucose-lowering efficacy is significantly reduced at this eGFR range. 5, 1, 2
eGFR 20-24 mL/min/1.73 m²: May initiate dapagliflozin 10 mg once daily for cardiovascular/renal protection based on recent evidence from EMPEROR trials showing safety and efficacy down to eGFR >20 mL/min/1.73 m². 5, 2
eGFR <20 mL/min/1.73 m²: Do NOT initiate dapagliflozin. However, if already on treatment when eGFR falls below 20 mL/min/1.73 m², continue 10 mg daily until dialysis is required. 2, 3
Empagliflozin Dosing by eGFR
Empagliflozin has more restrictive eGFR thresholds compared to dapagliflozin. 4
eGFR ≥45 mL/min/1.73 m²: Initiate empagliflozin 10 mg once daily, may increase to 25 mg once daily if additional glycemic control needed. Maximum dose is 25 mg once daily. 6, 4
eGFR <45 mL/min/1.73 m²: Do NOT initiate empagliflozin. Discontinue if eGFR falls persistently below 45 mL/min/1.73 m². 6, 4
Canagliflozin Dosing by eGFR
eGFR ≥60 mL/min/1.73 m²: Initiate canagliflozin 100 mg once daily, may increase to 300 mg once daily if additional glycemic control needed. 1, 7
eGFR 30-59 mL/min/1.73 m²: Maximum dose is 100 mg once daily. Do not exceed this dose. The CREDENCE trial used 100 mg daily in patients with eGFR 30-90 mL/min/1.73 m² and demonstrated significant renal and cardiovascular benefits. 1, 7
eGFR <30 mL/min/1.73 m²: Do NOT initiate or continue canagliflozin. 1, 7
Critical Clinical Algorithm for SGLT2 Inhibitor Selection in CKD
For patients with type 2 diabetes and CKD with eGFR 20-44 mL/min/1.73 m² and albuminuria ≥200 mg/g, prioritize dapagliflozin 10 mg once daily, as it has the strongest evidence from the DAPA-CKD trial specifically designed for kidney outcomes in this population. 5, 7, 3
eGFR ≥45 mL/min/1.73 m²: Any SGLT2 inhibitor can be used at standard doses. Choose based on formulary, cost, and patient preference. 1, 7
eGFR 30-44 mL/min/1.73 m²: Dapagliflozin 10 mg daily OR canagliflozin 100 mg daily are preferred. Empagliflozin is contraindicated. 5, 1, 7
eGFR 20-29 mL/min/1.73 m²: Only dapagliflozin 10 mg daily may be considered based on recent guideline updates. Canagliflozin and empagliflozin are contraindicated. 5, 2
Key Evidence Supporting Lower eGFR Thresholds
The DAPA-CKD trial enrolled patients with eGFR 25-75 mL/min/1.73 m² and UACR 200-5000 mg/g, demonstrating a 39% reduction in the primary composite endpoint (≥50% sustained eGFR decline, ESKD, or renal/cardiovascular death) with dapagliflozin 10 mg daily. 5, 3
Subgroup analyses from DAPA-CKD and the EMPEROR heart failure trials suggest that SGLT2 inhibitors are safe and effective at eGFR levels >20 mL/min/1.73 m², leading to the 2023 ADA recommendation to use SGLT2 inhibitors in individuals with eGFR as low as 20 mL/min/1.73 m². 5
Common Pitfalls to Avoid
Do NOT discontinue SGLT2 inhibitors solely because eGFR falls below 45 mL/min/1.73 m² during treatment—cardiovascular and renal protective benefits persist even when glycemic efficacy is lost. 1, 2
Do NOT withhold SGLT2 inhibitors based on HbA1c being at goal—the kidney and cardiovascular benefits are independent of glucose-lowering effects. 7
A reversible decrease in eGFR of 3-5 mL/min/1.73 m² typically occurs within the first 1-4 weeks of SGLT2 inhibitor initiation, which is transient and generally not an indication to discontinue therapy. 1, 2
Safety Monitoring Requirements
Assess volume status before initiating SGLT2 inhibitors, particularly in patients on loop diuretics, elderly patients (≥75 years), or those with low systolic blood pressure. Consider reducing concurrent diuretic doses to prevent excessive volume depletion. 1, 2, 7
Withhold SGLT2 inhibitors during acute illness (fever, vomiting, diarrhea, reduced oral intake) and at least 3 days before major surgery or procedures requiring prolonged fasting to prevent euglycemic diabetic ketoacidosis. 1, 2
Monitor for genital mycotic infections (occur in ~6% of patients vs 1% on placebo) and urinary tract infections. Educate patients about symptoms and prevention strategies. 1, 2
Recheck eGFR within 1-2 weeks after initiation, then at least every 3-6 months if eGFR 30-59 mL/min/1.73 m², or annually if eGFR ≥60 mL/min/1.73 m². 1, 2